Auxly’s Subsidiary KGK Science Receives Institutional Cannabis Research Licence from Health Canada
TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) — Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly” or the “Company”), a consumer packaged goods company in the cannabis products market, is thrilled to announce that its wholly owned subsidiary, KGK Science Inc. (“KGK”) has received its Institutional Cannabis Research Licence from Health Canada pursuant to the Cannabis Act. In addition to the two project-specific cannabis research licences, and the licence to conduct sensory trials currently held by KGK, this Institutional licence provides the contract research organization with approval to conduct multiple cannabis research projects, removing the need to obtain individual research licences for each project, thereby increasing its flexibility and expediting processes at its clinical research facility located in London, Ontario.As one of the first entities in Canada to receive this expanded licence, KGK will be able to provide its clients increased access to an expansive portfolio of clinical trials in support of the development of safe and effective cannabis products.“As the cannabis industry continues to evolve and we sit on the cusp of some major regulatory changes, this institutional research licence allows us to increase the pace by which we can support the industry in ensuring the safety and efficacy of cannabis products to Canadian consumers,” says KGK President and CEO Najla Guthrie. “With KGK’s in-depth expertise in the nutraceutical industry, our team of highly-trained scientific researchers, and access to state-of-the-art technologies, KGK continues to be positioned to lead the cannabis industry in research as it moves into its next stage of growth.”ON BEHALF OF THE BOARD “Hugo Alves“ CEO About Auxly Cannabis Group Inc. (TSX.V: XLY)
Auxly is an international cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the medical, wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.About KGK Science Inc.
KGK Science, a wholly owned subsidiary of Auxly, is a premium contract research organization (CRO) offering high-quality clinical research trials and expert regulatory support for the nutraceutical, cannabis and hemp industries. For over 22 years, KGK has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies that move products efficiently into global markets. Equipped with state-of-the-art technologies, novel research techniques, and a seasoned team of industry experts, KGK Science remains at the forefront of its industry, consolidating scientific, clinical, commercial, and regulatory expertise with innovation and agility to serve the expanding needs of global business and consumers. Visit us at www.kgkscience.comLearn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.Investor Relations:
For investor enquiries please contact our Investor Relations Team:
Phone: 1.833.695.2414Media Enquiries (only):
For media enquiries or to set up an interview please contact:
Email: firstname.lastname@example.org Notice Regarding Forward Looking Information:
This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the anticipated benefits of KGK’s research and development initiatives; the timing and outcome of regulatory decisions; consumer preferences; political change, future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting the Company and KGK in particular and the cannabis industry generally.A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release including, but not limited to, whether: KGK is able to maintain the Institutional Cannabis Research Licence and its other current licences, and obtain and maintain all other necessary governmental and regulatory authorizations and permits to conduct business; the success of KGK’s research strategies and the applicability of the discoveries made therein; and general economic, financial market, regulatory and political conditions in which the Company and KGK operate will remain the same. Additional risk factors are disclosed in the annual information form of the Company for the financial year ended December 31, 2019 dated May 13, 2020.New factors emerge from time to time, and it is not possible for management to predict all of those factors or to assess in advance the impact of each such factor on Auxly’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. In addition, this release may contain forward-looking information attributed to third party industry sources, the accuracy of which has not been verified by Auxly. The purpose of forward-looking information is to provide the reader with a description of management’s expectations, and such forward-looking information may not be appropriate for any other purpose. Readers should not place undue reliance on forward-looking information contained in this release. The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, Auxly does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.